Christopher A Beck1, Denise B Beran1, Kevin M Biglan1, Cynthia M Boyd1, E Ray Dorsey2, Peter N Schmidt1, Richard Simone1, Allison W Willis1, Nicholas B Galifianakis1, Maya Katz1, Caroline M Tanner1, Kristen Dodenhoff1, Jason Aldred1, Julie Carter1, Andrew Fraser1, Joohi Jimenez-Shahed1, Christine Hunter1, Meredith Spindler1, Suzanne Reichwein1, Zoltan Mari1, Becky Dunlop1, John C Morgan1, Dedi McLane1, Patrick Hickey1, Lisa Gauger1, Irene Hegeman Richard1, Nicte I Mejia1, Grace Bwala1, Martha Nance1, Ludy C Shih1, Carlos Singer1, Silvia Vargas-Parra1, Cindy Zadikoff1, Natalia Okon1, Andrew Feigin1, Jean Ayan1, Christina Vaughan1, Rajesh Pahwa1, Rohit Dhall1, Anhar Hassan1, Steven DeMello1, Sara S Riggare1, Paul Wicks1, Meredith A Achey1, Molly J Elson1, Steven Goldenthal1, H Tait Keenan1, Ryan Korn1, Heidi Schwarz1, Saloni Sharma1, E Anna Stevenson1, William Zhu1. 1. From the Department of Biostatistics and Computational Biology (C.A.B.), University of Rochester, NY; National Parkinson Foundation (D.B.B., P.N.S.), Miami, FL; Department of Neurology (K.M.B., E.R.D., I.H.R., H.S.) and The Center for Human Experimental Therapeutics (E.R.D., M.A.A., M.J.E., S.G., H.T.K., R.K., S.S., E.A.S., W.Z.), University of Rochester Medical Center, NY; Division of Geriatric Medicine and Gerontology, Department of Medicine (C.M.B., Z.M., B.D.), Johns Hopkins University School of Medicine, Baltimore, MD; Simone Consulting (R.S.), Sunnyvale, CA; Departments of Neurology and Biostatistics and Epidemiology (A.W.W., M.S., S.R.), University of Pennsylvania Perelman School of Medicine, Philadelphia; University of California San Francisco (N.B.G., M.K., C.M.T., K.D.); Northwest Neurological, PLLC (J. Aldred), Spokane, WA; Oregon Health and Science University (J.C., A. Fraser), Portland; Baylor College of Medicine (J.J.-S., C.H.), Houston, TX; Augusta University (J.C.M., D.M.), GA; Duke Medical Center (P.H., L.G.), Durham, NC; Massachusetts General Hospital (N.I.M., G.B.), Boston; Struthers Parkinson's Center (M.N.), Minneapolis, MN; Beth Israel Deaconess Medical Center (L.C.S.), Boston, MA; University of Miami (C.S., S.V.-P.), FL; Northwestern University (C.Z., N.O.), Evanston, IL; The Feinstein Institute for Medical Research (A. Feigin, J. Ayan), Northwell Health, Manhasset, NY; Medical University of South Carolina (C.V.), Charleston; University of Kansas Medical Center (R.P.), Kansas City; Parkinson's Institute (R.D.), Sunnyvale, CA; Mayo Clinic (A.H.), Rochester, MN; Center for Information Technology Research in the Interest of Society (CITRIS) (S.D.), University of California, Berkeley; Health Informatics Centre (S.S.R.), Karolinska Institute, Stockholm, Sweden; and PatientsLikeMe (P.W.), Derby, UK. 2. From the Department of Biostatistics and Computational Biology (C.A.B.), University of Rochester, NY; National Parkinson Foundation (D.B.B., P.N.S.), Miami, FL; Department of Neurology (K.M.B., E.R.D., I.H.R., H.S.) and The Center for Human Experimental Therapeutics (E.R.D., M.A.A., M.J.E., S.G., H.T.K., R.K., S.S., E.A.S., W.Z.), University of Rochester Medical Center, NY; Division of Geriatric Medicine and Gerontology, Department of Medicine (C.M.B., Z.M., B.D.), Johns Hopkins University School of Medicine, Baltimore, MD; Simone Consulting (R.S.), Sunnyvale, CA; Departments of Neurology and Biostatistics and Epidemiology (A.W.W., M.S., S.R.), University of Pennsylvania Perelman School of Medicine, Philadelphia; University of California San Francisco (N.B.G., M.K., C.M.T., K.D.); Northwest Neurological, PLLC (J. Aldred), Spokane, WA; Oregon Health and Science University (J.C., A. Fraser), Portland; Baylor College of Medicine (J.J.-S., C.H.), Houston, TX; Augusta University (J.C.M., D.M.), GA; Duke Medical Center (P.H., L.G.), Durham, NC; Massachusetts General Hospital (N.I.M., G.B.), Boston; Struthers Parkinson's Center (M.N.), Minneapolis, MN; Beth Israel Deaconess Medical Center (L.C.S.), Boston, MA; University of Miami (C.S., S.V.-P.), FL; Northwestern University (C.Z., N.O.), Evanston, IL; The Feinstein Institute for Medical Research (A. Feigin, J. Ayan), Northwell Health, Manhasset, NY; Medical University of South Carolina (C.V.), Charleston; University of Kansas Medical Center (R.P.), Kansas City; Parkinson's Institute (R.D.), Sunnyvale, CA; Mayo Clinic (A.H.), Rochester, MN; Center for Information Technology Research in the Interest of Society (CITRIS) (S.D.), University of California, Berkeley; Health Informatics Centre (S.S.R.), Karolinska Institute, Stockholm, Sweden; and PatientsLikeMe (P.W.), Derby, UK. ray.dorsey@chet.rochester.edu.
Abstract
OBJECTIVE: To determine whether providing remote neurologic care into the homes of people with Parkinson disease (PD) is feasible, beneficial, and valuable. METHODS: In a 1-year randomized controlled trial, we compared usual care to usual care supplemented by 4 virtual visits via video conferencing from a remote specialist into patients' homes. Primary outcome measures were feasibility, as measured by the proportion who completed at least one virtual visit and the proportion of virtual visits completed on time; and efficacy, as measured by the change in the Parkinson's Disease Questionnaire-39, a quality of life scale. Secondary outcomes included quality of care, caregiver burden, and time and travel savings. RESULTS: A total of 927 individuals indicated interest, 210 were enrolled, and 195 were randomized. Participants had recently seen a specialist (73%) and were largely college-educated (73%) and white (96%). Ninety-five (98% of the intervention group) completed at least one virtual visit, and 91% of 388 virtual visits were completed. Quality of life did not improve in those receiving virtual house calls (0.3 points worse on a 100-point scale; 95% confidence interval [CI] -2.0 to 2.7 points; p = 0.78) nor did quality of care or caregiver burden. Each virtual house call saved patients a median of 88 minutes (95% CI 70-120; p < 0.0001) and 38 miles per visit (95% CI 36-56; p < 0.0001). CONCLUSIONS: Providing remote neurologic care directly into the homes of people with PD was feasible and was neither more nor less efficacious than usual in-person care. Virtual house calls generated great interest and provided substantial convenience. CLINICALTRIALSGOV IDENTIFIER: NCT02038959. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with PD, virtual house calls from a neurologist are feasible and do not significantly change quality of life compared to in-person visits. The study is rated Class III because it was not possible to mask patients to visit type.
OBJECTIVE: To determine whether providing remote neurologic care into the homes of people with Parkinson disease (PD) is feasible, beneficial, and valuable. METHODS: In a 1-year randomized controlled trial, we compared usual care to usual care supplemented by 4 virtual visits via video conferencing from a remote specialist into patients' homes. Primary outcome measures were feasibility, as measured by the proportion who completed at least one virtual visit and the proportion of virtual visits completed on time; and efficacy, as measured by the change in the Parkinson's Disease Questionnaire-39, a quality of life scale. Secondary outcomes included quality of care, caregiver burden, and time and travel savings. RESULTS: A total of 927 individuals indicated interest, 210 were enrolled, and 195 were randomized. Participants had recently seen a specialist (73%) and were largely college-educated (73%) and white (96%). Ninety-five (98% of the intervention group) completed at least one virtual visit, and 91% of 388 virtual visits were completed. Quality of life did not improve in those receiving virtual house calls (0.3 points worse on a 100-point scale; 95% confidence interval [CI] -2.0 to 2.7 points; p = 0.78) nor did quality of care or caregiver burden. Each virtual house call saved patients a median of 88 minutes (95% CI 70-120; p < 0.0001) and 38 miles per visit (95% CI 36-56; p < 0.0001). CONCLUSIONS: Providing remote neurologic care directly into the homes of people with PD was feasible and was neither more nor less efficacious than usual in-person care. Virtual house calls generated great interest and provided substantial convenience. CLINICALTRIALSGOV IDENTIFIER: NCT02038959. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with PD, virtual house calls from a neurologist are feasible and do not significantly change quality of life compared to in-person visits. The study is rated Class III because it was not possible to mask patients to visit type.
Authors: E Ray Dorsey; Lisa M Deuel; Tiffini S Voss; Kara Finnigan; Benjamin P George; Sheelah Eason; David Miller; Jason I Reminick; Anna Appler; Joyce Polanowicz; Lucy Viti; Sandy Smith; Anthony Joseph; Kevin M Biglan Journal: Mov Disord Date: 2010-08-15 Impact factor: 10.338
Authors: R M Dubinsky; C Gray; D Husted; K Busenbark; B Vetere-Overfield; D Wiltfong; D Parrish; W C Koller Journal: Neurology Date: 1991-04 Impact factor: 9.910
Authors: Eric M Cheng; Kari Swarztrauber; Andrew D Siderowf; Mahmood S Eisa; Martin Lee; Stefanie Vassar; Erin Jacob; Barbara G Vickrey Journal: Mov Disord Date: 2007-03-15 Impact factor: 10.338
Authors: Stephen K Van Den Eeden; Caroline M Tanner; Allan L Bernstein; Robin D Fross; Amethyst Leimpeter; Daniel A Bloch; Lorene M Nelson Journal: Am J Epidemiol Date: 2003-06-01 Impact factor: 4.897
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: E Ray Dorsey; Alistair M Glidden; Melissa R Holloway; Gretchen L Birbeck; Lee H Schwamm Journal: Nat Rev Neurol Date: 2018-04-06 Impact factor: 42.937
Authors: H Ben-Pazi; P Browne; P Chan; E Cubo; M Guttman; A Hassan; J Hatcher-Martin; Z Mari; E Moukheiber; N U Okubadejo; A Shalash Journal: Curr Neurol Neurosci Rep Date: 2018-04-13 Impact factor: 5.081
Authors: M Kelley Erb; Daniel R Karlin; Bryan K Ho; Kevin C Thomas; Federico Parisi; Gloria P Vergara-Diaz; Jean-Francois Daneault; Paul W Wacnik; Hao Zhang; Tairmae Kangarloo; Charmaine Demanuele; Chris R Brooks; Craig N Detheridge; Nina Shaafi Kabiri; Jaspreet S Bhangu; Paolo Bonato Journal: NPJ Digit Med Date: 2020-01-17
Authors: Jori Fleisher; William Barbosa; Meghan M Sweeney; Sarah E Oyler; Amy C Lemen; Arash Fazl; Mia Ko; Talia Meisel; Naomi Friede; Geraldine Dacpano; Rebecca M Gilbert; Alessandro Di Rocco; Joshua Chodosh Journal: J Am Geriatr Soc Date: 2018-04-02 Impact factor: 5.562
Authors: Eudocia Q Lee; Michael Weller; Joohee Sul; Stephen J Bagley; Solmaz Sahebjam; Martin van den Bent; Manmeet Ahluwalia; Jian L Campian; Evanthia Galanis; Mark R Gilbert; Matthias Holdhoff; Glenn J Lesser; Frank S Lieberman; Minesh P Mehta; Marta Penas-Prado; Karisa C Schreck; Roy E Strowd; Michael A Vogelbaum; Tobias Walbert; Susan M Chang; L Burt Nabors; Stuart Grossman; David A Reardon; Patrick Y Wen Journal: Neuro Oncol Date: 2020-05-15 Impact factor: 12.300
Authors: Lindsay Ross; James Bena; Robert Bermel; Lauren McCarter; Zubair Ahmed; Harold Goforth; Neil Cherian; Jennifer Kriegler; Emad Estemalik; Matthew Stanton; Peter Rasmussen; Hubert H Fernandez; Imad Najm; Marisa McGinley Journal: Telemed J E Health Date: 2020-06-23 Impact factor: 3.536
Authors: Parul Dayal; Celia H Chang; William S Benko; Aaron M Ulmer; Stephanie S Crossen; Brad H Pollock; Jeffrey S Hoch; Jamie L Kissee; Leslie Warner; James P Marcin Journal: Neurol Clin Pract Date: 2019-08